CD8A and neoplasm: Preclinical studies demonstrate that VISTA inhibition significantly increases CD8+ T cell infiltration, enhances IFN-γ and TNF-α secretion, and restores anti-tumor immunity, particularly when combined with anti–PD-1 therapy in PD-1-resistant models (172).